Factor Therapeutics Ltd (FTT)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Factor Therapeutics Ltd (FTT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013277
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:オーストラリア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Factor Therapeutics Ltd (FTL), formerly Tissue Therapies Ltd is a developer of wound care therapeutics. The company develops treatments for acute and chronic wound healing applications such as chronic skin ulcers and burns. Its lead therapeutic candidate, VF-001 is a targeted growth factor which is being developed to treat venous leg ulcers. FTL offers cell culture reagents to enhance the growth of mammalian cells for cell-based therapies. The company’s VF-001 pursues the development of other product candidates which may be applicability to other wound care applications. It utilizes third parties for development and commercialization of its novel products. FTL is headquartered in Brisbane, Queensland, Australia.

Factor Therapeutics Ltd (FTT) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Factor Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Factor Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Factor Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Factor Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Factor Therapeutics Ltd, Medical Devices Deals, 2011 to YTD 2017 9
Factor Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Factor Therapeutics Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Licensing Agreements 11
Tissue Therapies Receives Intellectual Property from Queensland University of Technology 11
Equity Offering 12
Tissue Therapies Raises USD2.4 Million in Rights Offering of Shares 12
Tissue Therapies Raises USD2 Million in First Tranche of Private Placement of Shares 13
Tissue Therapies Completes Rights Offering Of Shares For US$4.5 Million 14
Tissue Therapies Announces Private Placement Of Shares For US$0.5 Million 16
Tissue Therapies Completes Private Placement Of Shares For US$3 Million 17
Tissue Therapies Announces Private Placement Of Shares For US$1.2 Million 19
Tissue Therapies Completes Rights Issue Of US$10 Million 20
Tissue Therapies Completes Private Placement Of US$6 Million 21
Factor Therapeutics Ltd – Key Competitors 22
Factor Therapeutics Ltd – Key Employees 23
Factor Therapeutics Ltd – Locations And Subsidiaries 24
Head Office 24
Other Locations & Subsidiaries 24
Appendix 25
Methodology 25
About GlobalData 25
Contact Us 25
Disclaimer 25

List of Tables
Factor Therapeutics Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Factor Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Factor Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Factor Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Factor Therapeutics Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
Factor Therapeutics Ltd, Medical Devices Deals, 2011 to YTD 2017 9
Factor Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Tissue Therapies Receives Intellectual Property from Queensland University of Technology 11
Tissue Therapies Raises USD2.4 Million in Rights Offering of Shares 12
Tissue Therapies Raises USD2 Million in First Tranche of Private Placement of Shares 13
Tissue Therapies Completes Rights Offering Of Shares For US$4.5 Million 14
Tissue Therapies Announces Private Placement Of Shares For US$0.5 Million 16
Tissue Therapies Completes Private Placement Of Shares For US$3 Million 17
Tissue Therapies Announces Private Placement Of Shares For US$1.2 Million 19
Tissue Therapies Completes Rights Issue Of US$10 Million 20
Tissue Therapies Completes Private Placement Of US$6 Million 21
Factor Therapeutics Ltd, Key Competitors 22
Factor Therapeutics Ltd, Key Employees 23
Factor Therapeutics Ltd, Other Locations 24
Factor Therapeutics Ltd, Subsidiaries 24

★海外企業調査レポート[Factor Therapeutics Ltd (FTT)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Evercore Inc:企業のM&A・事業提携・投資動向
    Evercore Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Evercore Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, …
  • United Orthopedic Corp (4129)-医療機器分野:企業M&A・提携分析
    Summary United Orthopedic Corp (UOC) is a medical device company that designs, manufactures and distributes orthopedic implants and instrument sets. The company’s product categories include knee replacement systems, hip replacement systems, and oncology products. Its hip replacement systems include …
  • Glidewell Laboratories:企業の戦略的SWOT分析
    Glidewell Laboratories - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Posco Daewoo Corp (047050):企業の財務・戦略的SWOT分析
    Posco Daewoo Corp (047050) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Mobile Telesystems:企業の戦略・SWOT・財務情報
    Mobile Telesystems - Strategy, SWOT and Corporate Finance Report Summary Mobile Telesystems - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Eurobio Scientific SA (ALEHT):企業の財務・戦略的SWOT分析
    Summary Eurobio Scientific SA (Eurobio), formerly Diaxonhit SA, a subsidiary of Hellenic Petroleum SA, is a biotechnology company that provides diagnostic products. The company provides products such as TQS, used in treatment of teanus and BJI InoPlex, used for the treatment of prosthetic infection. …
  • MediGene AG (MDG1):製薬・医療:M&Aディール及び事業提携情報
    Summary MediGene AG (MediGene) is a biotechnology company which develops drugs for the treatment of various types and stages of cancer with candidates in clinical and pre-clinical development. The company focuses on the development of personalized T-cell-based immunotherapies. Its core business deve …
  • Advicenne SA (ADVIC)-製薬・医療分野:企業M&A・提携分析
    Summary Advicenne SA (Advicenne) is a developer of pediatric medicines. The company’s product portfolio includes ADV6209, a liquid formulation of a benzodiazepine for moderate sedation and anesthetic premedication; ADV7103, a formulation in the form of micro-tablets for renal tubulopathies. It offer …
  • Stallergenes Greer plc (STAGR):企業の財務・戦略的SWOT分析
    Stallergenes Greer plc (STAGR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Bando Chemical Industries, Ltd. (5195):企業の財務・戦略的SWOT分析
    Bando Chemical Industries, Ltd. (5195) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • Clementia Pharmaceuticals Inc (CMTA):製薬・医療:M&Aディール及び事業提携情報
    Summary Clementia Pharmaceuticals Inc (Clementia) is a clinical stage biopharmaceutical company that focuses on the development of treatments for rare bone disorders and other diseases. Its lead product candidate Palovarotene is used for the treatment of fibrodysplasia ossificans progressiva (FOP), …
  • Sealed Air Corporation:企業のM&A・事業提携・投資動向
    Sealed Air Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Sealed Air Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions …
  • Philip Morris International Inc.:企業の戦略・SWOT・財務情報
    Philip Morris International Inc. - Strategy, SWOT and Corporate Finance Report Summary Philip Morris International Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Dah Sing Bank, Limited:企業の戦略・SWOT・財務情報
    Dah Sing Bank, Limited - Strategy, SWOT and Corporate Finance Report Summary Dah Sing Bank, Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Golden Ocean Group Limited:企業のM&A・事業提携・投資動向
    Golden Ocean Group Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Golden Ocean Group Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acqui …
  • Viettel Group:企業の戦略・SWOT・財務情報
    Viettel Group - Strategy, SWOT and Corporate Finance Report Summary Viettel Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Verona Pharma Plc (VRP)-製薬・医療分野:企業M&A・提携分析
    Summary Verona Pharma Plc (Verona Pharma) is a clinical-stage biotechnology company, which focuses on the research, discovery and development of first-in-class therapeutic drugs for the treatment of chronic respiratory and inflammatory diseases. The company's lead candidate, RPL554 is a bronchodilat …
  • Osaka Gas Co Ltd (9532):企業の財務・戦略的SWOT分析
    Osaka Gas Co Ltd (9532) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Grifols SA (GRF)-医療機器分野:企業M&A・提携分析
    Summary Grifols SA (Grifols) focuses at improving the health and well-being of people around the world. It carries out the research, development, manufacturing and marketing of plasma-derived therapies, hospital pharmacy products and diagnostic technology for clinical use. The company specializes in …
  • Global Marine Systems Ltd:電力:M&Aディール及び事業提携情報
    Summary Global Marine Systems Limited (Global Marine), a subsidiary of Bridgehouse Marine Limited, is a marine technology and engineering company. It provides submarine cable installation, maintenance and engineering services. Its capabilities include project management, subsea cable installation, s …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆